Social media

With over 10,000 journals and conferences to consider it’s an important question to answer. There are 50+ accessible points of metadata to use in focusing your selection for a publishing source. Schedule a demo to learn ...

Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...

Potent and long-lasting incretin receptor agonists like GLP-1 RAs target the molecular mechanisms underlying glucose metabolism. Learn why these therapies are ushering in a new era of multi-indication drug development in...

Deepali Suri shares her vision for the biotech sector in 2026 and beyond. With over two decades of experience across pharma, biotech, and CROs, she outlines a clear strategy to strengthen innovation, streamline develop...

Therapeutic developers can aid control of the HIV epidemic by creating simpler, longer-acting prevention methods that perform better in real-world settings. ICON's whitepaper details these advances and best practices for...

Demographic Matching in Organ Impairment Studies: Why It Matters Organ impairment (OI) studies are critical for safe and effective drug development—but did you know that demographic matching can make or break the accurac...

In 2025 ICON was recognised in global rankings by both TIME and Fortune magazines celebrating organisations excelling in financial stability and environmental sustainability. Learn more. https://ow.ly/aqkw50XSPP5

Continuing our series of articles discussing managing risk for medical devices, ICON’s regulatory expert Jeremy Tinkler turns his focus on the biological risk estimate and looks into the logical basis for the use of comp...

The key to estimating biological risk in medical devices is establishing a good comparison. However, identifying the right comparison can be challenging. In the latest blog in our managing risk for medical devices series...

Innovation is accelerating progress in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions bring together advanced formulation design, real-time dose flexibility, and world-class CMC expertise to si...

For medical device developers selecting the right AI model and data is crucial to capitalise on this powerful technology. Our new whitepaper explains best practices for AI-enabled devices. Learn about AI models, datase...

Do you know the difference between decision trees and random forests? Learn about AI models for SaMDs in our new whitepaper. Download it now to learn best practices for model and data selection. https://ow.ly/nI8g50XAzbq